Ardelyx Inc (ARDX)
8.72
+1.93
(+28.42%)
USD |
NASDAQ |
May 03, 16:00
8.70
-0.02
(-0.23%)
After-Hours: 20:00
Ardelyx Total Liabilities (Quarterly): 130.76M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 130.76M |
| September 30, 2023 | 98.22M |
| June 30, 2023 | 88.04M |
| March 31, 2023 | 91.60M |
| December 31, 2022 | 91.74M |
| September 30, 2022 | 77.81M |
| June 30, 2022 | 78.57M |
| March 31, 2022 | 65.22M |
| December 31, 2021 | 67.30M |
| September 30, 2021 | 89.42M |
| June 30, 2021 | 87.41M |
| March 31, 2021 | 79.48M |
| December 31, 2020 | 75.45M |
| September 30, 2020 | 67.22M |
| June 30, 2020 | 70.99M |
| March 31, 2020 | 67.56M |
| December 31, 2019 | 73.13M |
| September 30, 2019 | 70.25M |
| June 30, 2019 | 69.36M |
| March 31, 2019 | 74.29M |
| December 31, 2018 | 67.52M |
| Date | Value |
|---|---|
| September 30, 2018 | 65.22M |
| June 30, 2018 | 65.12M |
| March 31, 2018 | 13.86M |
| December 31, 2017 | 18.59M |
| September 30, 2017 | 16.47M |
| June 30, 2017 | 19.14M |
| March 31, 2017 | 20.08M |
| December 31, 2016 | 19.98M |
| September 30, 2016 | 18.42M |
| June 30, 2016 | 14.77M |
| March 31, 2016 | 12.75M |
| December 31, 2015 | 8.045M |
| September 30, 2015 | 12.94M |
| June 30, 2015 | 5.928M |
| March 31, 2015 | 47.40M |
| December 31, 2014 | 52.73M |
| September 30, 2014 | 54.43M |
| June 30, 2014 | 60.61M |
| March 31, 2014 | 41.79M |
| December 31, 2013 | 50.23M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
65.22M
Minimum
Mar 2022
130.76M
Maximum
Dec 2023
81.03M
Average
77.81M
Median
Sep 2022
Total Liabilities (Quarterly) Benchmarks
| Nektar Therapeutics | 267.05M |
| Rigel Pharmaceuticals Inc | 145.87M |
| Omeros Corp | 403.25M |
| Vistagen Therapeutics Inc | 7.783M |
| Karyopharm Therapeutics Inc | 376.64M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 297.58M |
| Shareholders Equity (Quarterly) | 166.82M |
| Debt to Equity Ratio | 0.2987 |
| Current Ratio | 4.884 |
| Net Debt Paydown Yield | -0.32% |